Tocilizumab, an IL-6 receptor antagonist, and Siltuximab, an anti-IL-6 antibody, have been shown to inhibit IL-6 signaling; they were initially studied for treating cytokine release syndrome, and clinical and preclinical studies are now underway to evaluate their efficacy in a variety of cancers (34, 35). Here, IL6 is linked to cancer.